Search Results

You are looking at 71 - 80 of 1,168 items for :

  • Refine by Access: All x
Clear All
Full access

Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng

stage IIIC endometrial cancer . Gynecol Oncol 2005 ; 99 : 689 – 695 . 26 Creutzberg CL van Putten WL Koper PC . Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre

Full access

Inga T. Lennes, Mara Bloom, Nie Bohlen, and Beverly Moy

more than 12 weeks from last definitive surgery ( Figure 1 ). As might be expected, failing to reach the target of chemotherapy sooner than 12 weeks from surgery was more commonly seen in patients who underwent initial surgery outside of the MGH Cancer

Full access

Joseph M. Herman, John P. Hoffman, Sarah P. Thayer, and Robert A. Wolff

limited metastatic burden of disease. Role of Surgical Management in Metastatic PCA A small number of studies have identified that surgery can have a statistically significant survival advantage in selected patients with minimal metastatic disease

Full access

Benjamin L. Franc, Timothy P. Copeland, Robert Thombley, Miran Park, Ben Marafino, Mitzi L. Dean, W. John Boscardin, Hope S. Rugo, David Seidenwurm, Bhupinder Sharma, Stephen R. Johnston, and R. Adams Dudley

patients who received comparable treatment regimens, treatment cohorts were classified via CPT codes based on the combination of breast surgery type and whether the patient received radiation therapy (RT) ( supplemental eAppendix 1 ). These patient groups

Full access

Tejaswi Mudigonda, Daniel J. Pearce, Brad A. Yentzer, Phillip Williford, and Steven R. Feldman

, and family physicians also administer treatment. 6 , 17 , 18 Treatment modalities for NMSC include excision and closure, electrodessication and curettage (EDC), cryosurgery, radiotherapy, topical treatment with imiquimod, and Mohs micrographic surgery

Full access

Martin C. Mahoney

Qualitative and quantitative approaches to risk assessment are useful for identifying women at increased risk for developing breast cancer for whom genetics consultation, individualized surveillance recommendations, or chemoprevention may be appropriate. A comprehensive medical and family history review can be used to stratify women into categories of breast cancer risk. A quantitative estimate of the probability of developing breast cancer can be determined using risk assessment tools, such as the Gail and Claus models. Women at increased risk for breast cancer may benefit from individualized approaches to breast cancer risk reduction. Prevention strategies for reducing breast cancer risk include lifestyle modifications, chemoprevention, surgical approaches, and pharmacotherapy.

Full access

Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta

Background Delays in delivery of care for head and neck squamous cell carcinoma (HNSCC) can increase risk of disease persistence or progression. 1 , 2 Among the various delay intervals in HNSCC treatment, delayed time from surgery to

Full access

Vishwajith Sridharan, Vinayak Muralidhar, Danielle N. Margalit, Roy B. Tishler, James A. DeCaprio, Manisha Thakuria, Guilherme Rabinowits, and Jonathan D. Schoenfeld

also abstracted treatment parameters, including cancer-directed surgery at the primary site, SLNB and/or lymph node removal, and use of RT. The SEER database codes for SLNB are included with codes for lymph node–specific surgery; there is limited

Full access

Traci LeMasters, S. Suresh Madhavan, Usha Sambamoorthi, Hannah W. Hazard-Jenkins, Kimberly M. Kelly, and Dustin Long

) following breast-conserving surgery (BCS) for patients aged ≥70 years with stage I, estrogen receptor (ER)–positive breast cancer and that they should receive adjuvant endocrine therapy (AET) based on the CALGB C9343 trial findings. 2 , 10 , 11 The second

Full access

Ya-Fu Cheng, Wei-Heng Hung, Heng-Chung Chen, Ching-Yuan Cheng, Ching-Hsiung Lin, Sheng-Hao Lin, and Bing-Yen Wang

studies. 6 Although many issues remain unresolved, most contemporary lung cancer studies include surgery in the multimodal treatment of cT1–3N2 disease. This study aimed to identify the optimal therapeutic method and surgical strategy for cT1–3N2 lung